InvestorsHub Logo
Followers 16
Posts 1062
Boards Moderated 0
Alias Born 09/01/2019

Re: None

Friday, 03/12/2021 6:14:44 PM

Friday, March 12, 2021 6:14:44 PM

Post# of 44690
I seen some posts inferring RLF/NRX are picking sub groups of patients, well look at what Merck is doing with their Drug.


https://www.clinicaltrialsarena.com/comment/ridgeback-mercks-molnupiravir-for-covid-19-has-moa-administration-advantages-but-phase-iia-faces-execution-obstacles-may-have-value-gaps/

BTW, NP-120 (Ifenprodil) Outperforms Merck’s Phase 3 Drug MK-7264 (Gefapixant) in an Acute Cough Study by 110%